Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids
Status:
Completed
Trial end date:
2018-11-29
Target enrollment:
Participant gender:
Summary
Non alcoholic fatty liver disease (NAFLD) imposes a high and increasing burden on the NHS,
yet there is presently no licensed treatment or validated approach to management. NAFLD
predisposes to increased risk of type 2 diabetes, increased risk of cardiovascular disease
and may progress to chronic irreversible liver disease.
In NAFLD patients, the investigators will test the hypothesis that treatment with long chain
n-3 fatty acid supplementation for 18 months favourably influences bio-markers for NAFLD and
risk factors for cardiovascular disease and type 2 diabetes.
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital Southampton NHS Foundation Trust
Collaborator:
National Institute for Health Research, United Kingdom